Colorectal Cancer Research Reagents

Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the second leading cause of cancer death globally, with approximately 1.9 million new cases annually. Treatment strategies are guided by RAS/BRAF mutation status (anti-EGFR eligibility), microsatellite instability status (MSI-H/dMMR for checkpoint immunotherapy), and HER2 amplification. The integration of circulating tumor DNA (ctDNA) for minimal residual disease detection is rapidly transforming adjuvant treatment decisions in stage II–III CRC.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Colorectal Cancer Research Reagents — key pathogenic pathways and research targets including RAS-MAPK signaling, EGFR-targeted therapy, MMR/MSI status, and CEA biomarker

Fig. 1 Key pathogenic pathways and research targets in colorectal cancer. KRAS/BRAF-MAPK oncogenic signaling, EGFR-targeted therapy axis, MMR/MSI-driven immunotherapy, and CEA serum biomarker. Key research targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key colorectal cancer research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

KRAS / NRAS — RAS mutations (KRAS exon 2/3/4 and NRAS) occur in approximately 50% of CRC and predict resistance to anti-EGFR therapy (cetuximab, panitumumab). Anti-KRAS antibodies and mutation-specific reagents support immunohistochemical screening, RAS pathway activation studies, and development of direct RAS inhibitors including the emerging KRAS G12C-targeted class (sotorasib, adagrasib).
→ Browse KRAS/NRAS antibodies & proteins

BRAF V600E — BRAF V600E mutations occur in 8–12% of CRC and are associated with poor prognosis and right-sided tumor location. The BEACON regimen (encorafenib + binimetinib + cetuximab) has established a new standard of care for BRAF-mutant metastatic CRC. Anti-BRAF V600E mutation-specific antibodies enable IHC-based rapid screening, molecular subtyping, and treatment response research.
→ Browse BRAF antibodies & proteins

MMR Proteins (MLH1, MSH2, MSH6, PMS2) — Loss of mismatch repair protein expression (dMMR) identifies microsatellite instability-high (MSI-H) tumors eligible for PD-1 checkpoint immunotherapy (pembrolizumab, nivolumab). Anti-MLH1, MSH2, MSH6, and PMS2 antibodies are validated for IHC-based MMR status determination — the standard-of-care biomarker test for immunotherapy eligibility in metastatic CRC.
→ Browse MMR protein antibodies

EGFR (HER1, ErbB1) — Epidermal growth factor receptor is overexpressed in the majority of CRC and serves as the therapeutic target for cetuximab and panitumumab in RAS wild-type tumors. Anti-EGFR antibodies support IHC expression profiling, receptor activation studies, and research into mechanisms of acquired resistance including EGFR ectodomain mutations (S492R).
→ Browse EGFR antibodies & proteins

CEA (CEACAM5) — Carcinoembryonic antigen is the most widely used serum biomarker for CRC surveillance and recurrence monitoring. Anti-CEA antibodies and recombinant CEA proteins support ELISA assay development, IHC tissue validation, and emerging CEA-targeted bispecific antibody and antibody-drug conjugate therapeutic research programs.
→ Browse CEA antibodies & proteins

References

1. Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet. 2019;394(10207):1467-1480. DOI

2. André T, Shiu K-K, Kim TW, et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207-2218. DOI

3. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-1356. DOI

4. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. N Engl J Med. 2019;381(17):1632-1643. DOI

5. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-337. DOI